ES2044881T3 - Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano. - Google Patents

Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano.

Info

Publication number
ES2044881T3
ES2044881T3 ES87111726T ES87111726T ES2044881T3 ES 2044881 T3 ES2044881 T3 ES 2044881T3 ES 87111726 T ES87111726 T ES 87111726T ES 87111726 T ES87111726 T ES 87111726T ES 2044881 T3 ES2044881 T3 ES 2044881T3
Authority
ES
Spain
Prior art keywords
human cytomegalovirus
procedure
preparation
immunogenous
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87111726T
Other languages
English (en)
Inventor
Gerhard Dr Jahn
Birgit-Christine Scholl
Michael Dr Broker
Michael Dr Mach
Bernard Prof Fleckenstein
Bernd Traupe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Application granted granted Critical
Publication of ES2044881T3 publication Critical patent/ES2044881T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PROTEINA ESTRUCTURAL FOSFORILADA, DE PESO MOLECULAR DE UNOS 150 KD (PP 150) DEL CITOMEGALOVIRUS HUMANO (HCMV) ES FUERTEMENTE INMUNOGENA Y LOS ANTISUEROS HUMANOS LA RECONOCEN DE FORMA FIABLE. ESTA PROTEINA, UNA VEZ REFERIDA AL GENOMA DE HCMV, PUEDE OBTENERSE POR IGENIERIA GENETICA EN FORMA COMPLETA O EN ZONAS INMUNOGENAS PARCIALES. ESTAS PROTEINAS SON ADECUADAS COMO REACTIVO, POR EJEMPLO EN EL ENSAYO ELISA, Y COMO COMPONENTES DE VACUNAS
ES87111726T 1986-06-12 1987-06-05 Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano. Expired - Lifetime ES2044881T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3619718 1986-06-12

Publications (1)

Publication Number Publication Date
ES2044881T3 true ES2044881T3 (es) 1994-01-16

Family

ID=6302829

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87111726T Expired - Lifetime ES2044881T3 (es) 1986-06-12 1987-06-05 Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano.

Country Status (8)

Country Link
US (2) US5728578A (es)
EP (1) EP0252531B1 (es)
JP (2) JP2732840B2 (es)
AT (1) ATE82985T1 (es)
AU (1) AU605155B2 (es)
DE (1) DE3782867D1 (es)
ES (1) ES2044881T3 (es)
GR (1) GR3007031T3 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330051B1 (de) * 1988-02-24 1996-01-03 BEHRINGWERKE Aktiengesellschaft Strukturelles Phosphoprotein (pp28) des menschlichen Cytomegalovirus (HCMV), seine Herstellung und Verwendung
US5591439A (en) * 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
DK0389286T3 (da) * 1989-03-24 1996-11-18 Wistar Inst Rekombinant-cytomegalovirus-vaccine
US5552143A (en) * 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9014652D0 (en) * 1990-07-02 1990-08-22 Wellcome Found Antigen
DE4128684A1 (de) * 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
US5744298A (en) * 1991-08-29 1998-04-28 Behringwerke Aktiengesellschaft DNA sequences which encode immunoreactive HCMV-specific peptides
US6448389B1 (en) 1996-04-23 2002-09-10 The Wistar Institute Of Anatomy And Biology Human cytomegalovirus DNA constructs and uses therefor
CA2425202C (en) 2000-10-20 2012-01-03 City Of Hope Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150
US20040228842A1 (en) * 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
MX2012007489A (es) 2009-12-23 2012-11-29 4Antibody Ag Miembros enlazadores para citomegalovirus.
CN104569387B (zh) * 2015-01-13 2017-06-16 必欧瀚生物技术（合肥）有限公司 一种ELISA检测人血清HCMV pp150 IgM抗体试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4554159A (en) * 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4762780A (en) * 1984-04-17 1988-08-09 The Regents Of The University Of California Method and composition for screening and diagnosing "HCMV"
GB8404368D0 (en) * 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US4743562A (en) * 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US4689225A (en) * 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4808518A (en) * 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay

Also Published As

Publication number Publication date
EP0252531B1 (de) 1992-12-02
US5846733A (en) 1998-12-08
AU605155B2 (en) 1991-01-10
GR3007031T3 (es) 1993-07-30
AU7412887A (en) 1987-12-17
EP0252531A1 (de) 1988-01-13
JPH10113190A (ja) 1998-05-06
US5728578A (en) 1998-03-17
JP2732840B2 (ja) 1998-03-30
JPS62296893A (ja) 1987-12-24
DE3782867D1 (en) 1993-01-14
JP3272641B2 (ja) 2002-04-08
ATE82985T1 (de) 1992-12-15

Similar Documents

Publication Publication Date Title
ES2044881T3 (es) Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano.
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DE3856588D1 (de) Biologisch-aktive Bakterizide/permeabilitätserhöhende Proteinbruchstücke
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DK714788D0 (da) Polypeptider og derivater deraf samt deres anvendelse i pharmaceutiske og diagnostiske praeparater
RU95115239A (ru) Аналог эритропоэтина
FI870261A (fi) Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
Sutoh et al. N-terminal and C-terminal segments of actin participate in binding depactin, an actin-depolymerizing protein from starfish oocytes
DK110190A (da) Alveolaere surfaktantproteiner
DK0437604T3 (da) Rekombinant poxvirus- og streptokok M-proteinvaccine
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
DE3751632D1 (de) Expression von biologisch-aktiven PDGF-Analogen in eukaryotischen Zellen
ES2115622T5 (es) Clones moleculares de hiv-1 y usos de los mismos.
Ohtsuka et al. Possible cytoskeletal association of 69,000-and 68,000-dalton heat shock proteins and structural relations among heat shock proteins in murine mastocytoma cells
DE3752131D1 (de) Impfstoffe und diagnosetest für haemophilus influenzae
Leão Ferreira et al. Rearrangement of intermediate filament network of BHK-21 cells infected with vaccinia virus
US20240158452A1 (en) Materials and methods for inducing regulatory t cells
ES2068893T3 (es) Nuevos peptidos, su uso como inmuno-supresores y procedimientos para su preparacion.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
DK35891D0 (da) Praktisk taget rent, antigenisk peptid eller protein med en epitop af haemophilus influenzae, dets fremstilling og anvendelse
ES2056787T3 (es) Factor angiogenico de placenta humana capaz de estimular la sintesis capilar de proteasa de celulas endoteliales, la sintesis de adn y la migracion.
ES2057579T3 (es) Peptidos e1 y c de rubeola.
ES2032812T3 (es) Vacuna.
Imamura et al. Identification of a 115-kDa protein from muscle tissues: expression of a novel nonmuscle α-actinin in vascular endothelial cells
NO874704L (no) Minaktivin fremstilt ved rekombinant dna-teknikk.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 252531

Country of ref document: ES